Featured Story Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution July 1, 2024-Sera Prognostics
Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors June 26, 2024-Epitel
PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment September 1, 2022-PanTher Therapeutics
Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models August 1, 2022-Instylla Inc.
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent May 31, 2022-PanTher Therapeutics
Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting May 20, 2022-Sera Prognostics
Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project May 5, 2022-Sera Prognostics